Today: 12 June 2026
Browse Category

NASDAQ:REGN 24 September 2025 - 19 May 2026

Regeneron stock sinks after cancer trial miss prompts selloff

Regeneron stock sinks after cancer trial miss prompts selloff

Regeneron Pharmaceuticals shares fell 9.8% to $629.68 Monday after its late-stage melanoma drug trial with fianlimab failed to meet the main goal. The study did not show a statistically significant benefit over Merck’s Keytruda. At least 10 brokerages cut price targets. The decline outpaced broader market losses, with the Nasdaq down 0.5%.
19 May 2026
·
Regeneron Opens Lower After Cancer Trial Setback

Regeneron Opens Lower After Cancer Trial Setback

Regeneron shares dropped 11.8% in premarket trading Monday after its melanoma drug combo failed to meet the main goal in a late-stage trial. The high-dose fianlimab and cemiplimab combination showed a median progression-free survival of 11.5 months versus 6.4 months for Merck’s Keytruda, but missed statistical significance. Citi downgraded the stock and cut its price target to $700. Regeneron shares closed Friday at $698.25.
18 May 2026
··
Regeneron Earnings Beat, But Eylea Still Clouds REGN Stock

Regeneron Earnings Beat, But Eylea Still Clouds REGN Stock

Regeneron Pharmaceuticals reported first-quarter revenue of $3.605 billion, up 19%, and adjusted earnings of $9.47 per share, both above analyst estimates. Dupixent sales rose 33% and Libtayo 54%, while total U.S. Eylea sales fell 10%. Shares dropped 1.1% premarket. The FDA delayed a decision on a second Eylea HD syringe manufacturer; Regeneron cut its 2026 gross-margin forecast due to repairs in Ireland.
29 April 2026
···
Regeneron Stock Is Back In Focus: Why Wall Street Sees More Upside After Trump Deal

Regeneron Stock Is Back In Focus: Why Wall Street Sees More Upside After Trump Deal

Regeneron shares rose 2.6% Thursday after the company announced a U.S. drug-pricing agreement and said it would offer its new Otarmeni gene therapy free in the U.S. The stock closed at $766.02, up for the week and month but down 1.3% year to date. Raymond James and Cantor Fitzgerald reiterated bullish ratings and high price targets ahead of first-quarter results due April 29.
24 April 2026
··
Healthcare stocks brace for a busy week as XLV slips, UnitedHealth earnings and Capitol Hill heat loom

Healthcare stocks brace for a busy week as XLV slips, UnitedHealth earnings and Capitol Hill heat loom

XLV fell 0.51% to $157.48 Friday, trailing the S&P 500, which ended flat. Health insurer CEOs faced House scrutiny over rising premiums and consolidation, with UnitedHealth pledging ACA rebates in 2026. UnitedHealth reports earnings Jan. 27, Regeneron on Jan. 30. Corcept Therapeutics jumped 45% after positive ovarian cancer trial results.
24 January 2026
·····
Regeneron (REGN) Price Target Hits $1,057 as BMO and Canaccord Lift Forecasts on Dupixent Growth

Regeneron (REGN) Price Target Hits $1,057 as BMO and Canaccord Lift Forecasts on Dupixent Growth

BMO Capital raised its Regeneron price target to $850, citing Dupixent momentum and improved Eylea HD trends. Canaccord Genuity set a Street-high target of $1,057, expecting Dupixent growth to offset Eylea declines. Regeneron now holds a “Moderate Buy” consensus from 28 analysts, with an average target near $768. The stock has surged over 50% in six months amid active institutional trading.
4 December 2025
·
Regeneron Pharmaceuticals (REGN) Stock Outlook: Morgan Stanley Downgrade, Eylea HD Win and Gene‑Editing Push – December 3, 2025Regeneron

Regeneron Pharmaceuticals (REGN) Stock Outlook: Morgan Stanley Downgrade, Eylea HD Win and Gene‑Editing Push – December 3, 2025Regeneron

Regeneron shares traded near $725 midday December 3, down 2%, after Morgan Stanley downgraded the stock to Equal Weight with a $767 target, citing limited near-term upside. Eylea HD received U.S. approval for less frequent dosing in retinal vein occlusion. Market cap stands at about $77 billion, with a 0.5% dividend yield and trailing P/E of 17–18. Year-to-date total return is roughly 3%.
3 December 2025
··
NYSE Rollercoaster: Fed Caution Halts Tech Rally, Mega-Deals & Gold Spike in Wild 48 Hours

NYSE Rollercoaster: Fed Caution Halts Tech Rally, Mega-Deals & Gold Spike in Wild 48 Hours

Wall Street’s AI-fueled rally stalled Sept. 23 as the Nasdaq fell 0.95% and S&P 500 dropped 0.6% after Fed Chair Jerome Powell warned on rates and valuations. Tech stocks led declines, with Nvidia down 3% and Oracle off 4%. Gold hit a record near $3,764/oz as investors sought safety. Micron jumped 3% after strong earnings and an upbeat AI outlook.
24 September 2025
·················

Stock Market Today

  • Hays Shares See Slight Fair Value Reduction as Analysts Reassess Outlook
    June 11, 2026, 10:59 PM EDT. Hays (LSE:HAS) experienced a modest fair value cut from £0.42 to £0.41 amid cautious analyst sentiment. RBC Capital remains optimistic, highlighting Hays' global reach and diversified client base as potential upside drivers if hiring activity stabilizes. However, Citi downgraded the stock, citing concerns over execution and revenue trends, leading to questions about the company's ability to convert fees into steady earnings. Recent leadership changes include the appointment of Mark Dearnley as CEO, who brings extensive digital transformation experience. The downward adjustment also reflects a slightly weaker revenue growth forecast, now expected to decline by 2.17%. Analysts' mixed views underscore ongoing valuation risks and uncertainty in Hays' near-term outlook.

Latest articles

AI Names Drop, Oil Upends Inflation Bets, US Stocks Slip

Dow up 930 points after hours as tech lifts Nasdaq

12 June 2026
Dow soars 929.97 points for its strongest session in months as easing geopolitical risk and a rebound in tech drive ETFs higher after hours; chip stocks surge with the PHLX Semiconductor Index up 7.9%, while Adobe drops 5.44% after CFO exit despite raised forecasts.
Keel Infrastructure (KEEL) shares surge after $458 million AI data center deal closes

Keel Infrastructure (KEEL) shares surge after $458 million AI data center deal closes

12 June 2026
Keel Infrastructure Corp. surged 5.14% to $5.52 after closing $458 million in 1.250% convertible senior notes due 2032, with proceeds aimed at accelerating AI and high-performance computing data center projects; the notes’ initial conversion price is $7.41, about 25% above the June 4 close, while analysts’ 12-month price targets range from $3.00 to $8.00, averaging $5.52.
Go toTop